Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3-4
|
| pubmed:dateCreated |
1993-8-12
|
| pubmed:abstractText |
Described are two alternatives to the weighing of patients for assessing the dose of ivermectin for use in mass chemotherapy campaigns against onchocerciasis. The first method uses height to separate patients into four dosing categories (1/2, 1, 11/2 and 2 tablets), while the second involves estimating one of these dosing categories according to an individual's physical appearance, without making any measurements. Data for the height-based method were obtained from 6373 people who were taking part in a placebo-controlled trial of ivermectin in northern Nigeria. Use of an arbitrary trade-off of approximately 100 people "overdosed" for every person "underdosed" would lead to 0.5% of the population being underdosed by 1/2 tablet, 46.5% being dosed correctly, 51.7% being overdosed by 1/2 tablet, and 1.2% being overdosed by 1 tablet. The physical appearance approach involved three observers and 779 subjects. A total of 82% of the observers' estimates were "correct", with all the incorrect dosing deviating by only 1/2 tablet from the dose that the subjects should have received.
|
| pubmed:commentsCorrections | |
| pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/Africa,
http://linkedlifedata.com/resource/pubmed/keyword/Africa South Of The Sahara,
http://linkedlifedata.com/resource/pubmed/keyword/BODY HEIGHT,
http://linkedlifedata.com/resource/pubmed/keyword/Biology,
http://linkedlifedata.com/resource/pubmed/keyword/Body Weight,
http://linkedlifedata.com/resource/pubmed/keyword/Clinical Research,
http://linkedlifedata.com/resource/pubmed/keyword/Clinical Trials,
http://linkedlifedata.com/resource/pubmed/keyword/Developing Countries,
http://linkedlifedata.com/resource/pubmed/keyword/Diseases,
http://linkedlifedata.com/resource/pubmed/keyword/Double-blind Studies,
http://linkedlifedata.com/resource/pubmed/keyword/Drugs--administraction and dosage,
http://linkedlifedata.com/resource/pubmed/keyword/English Speaking Africa,
http://linkedlifedata.com/resource/pubmed/keyword/Examinations And Diagnoses,
http://linkedlifedata.com/resource/pubmed/keyword/Health,
http://linkedlifedata.com/resource/pubmed/keyword/NIGERIA,
http://linkedlifedata.com/resource/pubmed/keyword/Ophthalmological Effects,
http://linkedlifedata.com/resource/pubmed/keyword/PARASITIC DISEASES,
http://linkedlifedata.com/resource/pubmed/keyword/PUBLIC HEALTH,
http://linkedlifedata.com/resource/pubmed/keyword/Parasite Control,
http://linkedlifedata.com/resource/pubmed/keyword/Physical Examinations And Diagnoses,
http://linkedlifedata.com/resource/pubmed/keyword/Physiology,
http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology,
http://linkedlifedata.com/resource/pubmed/keyword/Research Report,
http://linkedlifedata.com/resource/pubmed/keyword/Studies,
http://linkedlifedata.com/resource/pubmed/keyword/Treatment,
http://linkedlifedata.com/resource/pubmed/keyword/Western Africa
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0042-9686
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
71
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
361-6
|
| pubmed:dateRevised |
2009-11-18
|
| pubmed:otherAbstract |
PIP: Between December 1988 and October 1989, 6373 inhabitants of 34 rural communities in Kaduna State in northern Nigeria participated in a double-blind, placebo controlled trial of ivermectin for onchocerciasis, in which height was used to determine the dose of ivermectin. In December, 1991, the field team estimated the correct dose of ivermectin solely on the physical appearance of 779 people. Researchers conducted these studies to determine whether these methods could replace weight as a reliable assessment of the dose of ivermectin. (Use of weight poses practical problems, e.g., providing and maintaining many weighing scales in rural areas.) Most participants were assigned a dose of ivermectin that deviated by no more than 1/2 tablet from the correct dose (98.8% for height method and 100% for physical appearance method). The physical appearance method was more successful at determining the correct use than the height method (82 vs. 46.5%). These studies revealed that few underdosings occurred, and they were no more than 1/2 tablet (e.g., 0.5% for height method). This findings was especially important, since underdosing does not effectively destroy the microfiliarae of Onchocerca volvulus, while overdosing causes no harm. The researchers concluded that both the height and physical appearance methods would be appropriate alternative methods to assess the ivermectin dose for people in rural communities. Further research on both methods in different settings and populations would identify which one should become the method of choice.
|
| pubmed:meshHeading |
pubmed-meshheading:8324855-Adult,
pubmed-meshheading:8324855-Body Height,
pubmed-meshheading:8324855-Body Weight,
pubmed-meshheading:8324855-Child, Preschool,
pubmed-meshheading:8324855-Drug Administration Schedule,
pubmed-meshheading:8324855-Female,
pubmed-meshheading:8324855-Humans,
pubmed-meshheading:8324855-Infant,
pubmed-meshheading:8324855-Ivermectin,
pubmed-meshheading:8324855-Male,
pubmed-meshheading:8324855-Onchocerciasis
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Ivermectin dose assessment without weighing scales.
|
| pubmed:affiliation |
Guinness Ophthalmic Unit, Ahmadu Bello University Teaching Hospital, Kaduna, Nigeria.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|